Quince Therapeutics, Inc. Total Liabilities
Quince Therapeutics, Inc. total liabilities. Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has total liabilities worth $15.51 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Quince Therapeutics, Inc. (QNCX) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Quince Therapeutics, Inc. (2017–2025)
Total liabilities of Quince Therapeutics, Inc. from 2017 to 2025. This chart illustrates how Quince Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore QNCX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Quince Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Quince Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PTRB
KLSE:0260
|
Malaysia | RM184.59 Million |
|
Rockwell Medical Inc
NASDAQ:RMTI
|
USA | $21.44 Million |
|
Xu Yuan Packaging Technology Co Ltd
TWO:8421
|
Taiwan | NT$1.22 Billion |
|
Auctus Alternative Investments Ltd
AU:AVC
|
Australia | AU$6.61 Million |
|
Comunication Weaver Co.Ltd
KQ:056360
|
Korea | ₩27.91 Billion |
|
Euro Holdings Bhd
KLSE:7208
|
Malaysia | RM40.08 Million |
|
Shemaroo Entertainment Limited
NSE:SHEMAROO
|
India | Rs-2.67 Billion |
|
North Energy ASA
OL:NORTH
|
Norway | Nkr104.21 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Quince Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see QNCX asset base.
Liquidity & Leverage Metrics
Quince Therapeutics, Inc. Total Liabilities Ratios Explained
Quince Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quince Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quince Therapeutics, Inc. (2017–2025)
The table below shows the annual total liabilities of Quince Therapeutics, Inc. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $129.24 Million | +53.25% |
| 2024-12-31 | $84.33 Million | -11.34% |
| 2023-12-31 | $95.12 Million | +2767.65% |
| 2022-12-31 | $3.32 Million | -77.35% |
| 2021-12-31 | $14.64 Million | -14.89% |
| 2020-12-31 | $17.20 Million | +93.48% |
| 2019-12-31 | $8.89 Million | +510.30% |
| 2018-12-31 | $1.46 Million | -94.80% |
| 2017-12-31 | $28.00 Million | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more